Suppr超能文献

Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle.

作者信息

Van't Veen A, Gommers D, Verbrugge S J, Wollmer P, Mouton J W, Kooij P P, Lachmann B

机构信息

Department of Anaesthesiology, Erasmus Medical Centre Rotterdam, The Netherlands.

出版信息

Br J Pharmacol. 1999 Mar;126(5):1091-6. doi: 10.1038/sj.bjp.0702405.

Abstract
  1. The use of pulmonary exogenous surfactant as a vehicle for intratracheally administered antibiotics to improve local antimicrobial therapy has been proposed. The present study investigated lung clearance rates in the rat of intratracheally instilled technetium labelled tobramycin with and without the addition of surfactant to the antibiotic solution. 2. The influence of surfactant on 99mTc-tobramycin lung clearance rates was studied dynamically with a gamma-camera in anaesthetized spontaneously breathing animals and in mechanically ventilated animals. 3. The results show that instillation of 99mTc-tobramycin with use of surfactant as vehicle significantly increases 99mTc-tobramycin lung clearance compared to instillation of 99mTc-tobramycin solution alone (P=0.006 between the two spontaneously breathing groups of animals and P=0.02 between the two ventilated groups of animals, ANOVA for repeated time measurements). The half life (t1/2) of composite clearance curves in spontaneous breathing animals was 147 min for animals receiving 99mTc-tobramycin versus 61 min for animals receiving 99mTc-tobramycin with surfactant. In mechanically ventilated animals this was 163 min versus 51 min, respectively. 4. It is concluded that exogenous surfactant, used as vehicle for intratracheally instilled 99mTc-tobramycin, increases lung clearance rate of 99mTc-tobramycin in rats.
摘要

相似文献

1
Lung clearance of intratracheally instilled 99mTc-tobramycin using pulmonary surfactant as vehicle.
Br J Pharmacol. 1999 Mar;126(5):1091-6. doi: 10.1038/sj.bjp.0702405.
2
Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae.
Br J Pharmacol. 1996 Nov;119(6):1145-8. doi: 10.1111/j.1476-5381.1996.tb16016.x.
3
Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity.
Br J Pharmacol. 1996 Jun;118(3):593-8. doi: 10.1111/j.1476-5381.1996.tb15442.x.
4
Short-term distribution kinetics of intratracheally administered exogenous lung surfactant.
Pediatr Res. 1992 May;31(5):445-50. doi: 10.1203/00006450-199205000-00006.
5
Tobramycin disposition in the rat lung following airway administration.
J Pharmacol Exp Ther. 2013 Nov;347(2):318-24. doi: 10.1124/jpet.113.207415. Epub 2013 Sep 5.
6
Spontaneous breathing or mechanical ventilation alters lung compliance and tissue association of exogenous surfactant in preterm newborn rabbits.
Pediatr Res. 2005 May;57(5 Pt 1):624-30. doi: 10.1203/01.PDR.0000156502.84909.BC. Epub 2005 Feb 17.
7
Pulmonary 99mTc-human serum albumin clearance and effects of surfactant replacement after lung lavage in rabbits.
Crit Care Med. 1996 Sep;24(9):1518-23. doi: 10.1097/00003246-199609000-00015.
8
Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients.
J Antimicrob Chemother. 2004 Aug;54(2):508-14. doi: 10.1093/jac/dkh326. Epub 2004 Jun 23.
10
Pulmonary clearance of 99mTc-DTPA in experimental surfactant dysfunction treated with surfactant instillation.
Acta Anaesthesiol Scand. 1997 Feb;41(2):297-303. doi: 10.1111/j.1399-6576.1997.tb04682.x.

引用本文的文献

1
Barriers that Inhaled Particles Encounter.
J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):299-306. doi: 10.1089/jamp.2024.27498.bp.
2
Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans.
Eur J Clin Microbiol Infect Dis. 2024 May;43(5):927-936. doi: 10.1007/s10096-024-04799-7. Epub 2024 Mar 14.
3
Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned.
Respir Res. 2021 Feb 26;22(1):71. doi: 10.1186/s12931-020-01585-9.
4
Pulmonary surfactant and drug delivery: Vehiculization, release and targeting of surfactant/tacrolimus formulations.
J Control Release. 2021 Jan 10;329:205-222. doi: 10.1016/j.jconrel.2020.11.042. Epub 2020 Nov 24.
7
Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin.
J Aerosol Med Pulm Drug Deliv. 2014 Oct;27(5):392-9. doi: 10.1089/jamp.2013.1058. Epub 2014 Jan 29.
8
A cell-based computational modeling approach for developing site-directed molecular probes.
PLoS Comput Biol. 2012;8(2):e1002378. doi: 10.1371/journal.pcbi.1002378. Epub 2012 Feb 23.
9
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.
Antimicrob Agents Chemother. 2004 May;48(5):1441-53. doi: 10.1128/AAC.48.5.1441-1453.2004.

本文引用的文献

2
Exogenous surfactant enhances the delivery of recombinant adenoviral vectors to the lung.
Hum Gene Ther. 1997 Jan 20;8(2):171-6. doi: 10.1089/hum.1997.8.2-171.
3
Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis.
Antimicrob Agents Chemother. 1997 Jan;41(1):184-7. doi: 10.1128/AAC.41.1.184.
5
Pulmonary surfactant as vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae.
Br J Pharmacol. 1996 Nov;119(6):1145-8. doi: 10.1111/j.1476-5381.1996.tb16016.x.
6
Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity.
Br J Pharmacol. 1996 Jun;118(3):593-8. doi: 10.1111/j.1476-5381.1996.tb15442.x.
7
Inhalation of antibiotics in cystic fibrosis.
Eur Respir J. 1995 Sep;8(9):1594-604.
8
9
Efficacy of aerosolized tobramycin in patients with cystic fibrosis.
N Engl J Med. 1993 Jun 17;328(24):1740-6. doi: 10.1056/NEJM199306173282403.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验